Share
French medication intelligence company Synapse Medicine has rolled-out its Medication Shield technology in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).
The technology claims to increase the safety of the COVID-19 vaccination campaign in France by managing the adverse drug reactions (ADRs) signals on a reporting portal, which is implemented by the French Ministry of Health.
The reactions are encoded automatically into a standardised international terminology (MedDRA) which ranks them by severity.
Synapse Medicine has been working in collaboration with the health institutions for the last 18 months on the management of pharmacovigilance cases. They have since published an infographic explaining how the Medication Shield technology is integrated into the French pharmacovigilance system.
Article content
Two Canadian cannabis companies are among a mere handful of businesses to be providing cannabis-related products for a medical marijuana trial in France involving 3,000 patients.
After being judged on product, manufacturing and supply criteria, both Tilray and Aurora Cannabis made the cut. Like the other companies involved in the pilot project, all medicine will be supplied free of charge to both the French government and the participating patients.
We apologize, but this video has failed to load.
Try refreshing your browser, or Tilray and Aurora among select few to provide medicinal cannabis products for French trial Back to video
Author Bio
Rich has been a Fool since 1998 and writing for the site since 2004. After 20 years of patrolling the mean streets of suburbia, he hung up his badge and gun to take up a pen full time. Having made the streets safe for Truth, Justice, and Krispy Kreme donuts, he now patrols the markets looking for companies he can lock up as long-term holdings in a portfolio.
His coverage reflects his passion for motorcycles, booze, and guns (though typically not all exercised at the same time), but his writing also covers the broader sectors of consumer goods, technology, and industrials. So follow along as he tries to break down complex topics to make them more understandable and useful to the average investor.
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
NOVA awarded €2.4 million
to leverage Jinko®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease
1
2 -
to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab
ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare and life-threatening disease
Lyon, France – 19 January 2021: The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery (“NOVA”) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graf
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
NOVA awarded €2.4 million
to leverage Jinko, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease
Research academic teams of the consortium - Institut de Recherche Saint Louis
1
2 -
to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab
ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare and life-threatening disease
Lyon, France - 19 January 2021: The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery ( NOVA ) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to